Briefs: Wanbury and Bafna Pharmaceuticals

Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API

Granules India’s Gagillapur facility completes USFDA inspection with six observations

The recent inspection covered both cGMP and PAI processes

Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug

Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business

TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry

Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25

Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market

Enzene appoints new site lead of biologics manufacturing

He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site

NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%

Zydus receives USFDA final approval for Scopolamine Transdermal System 1 mg/3 days

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025